Delray Beach – November 06, 2026 -- The global high-performance liquid chromatography (HPLC) market is projected to grow from USD 7.86 billion in 2026 to USD 12.2 billion by 2031, a compound annual growth rate of 9.3%, according to MarketsandMarkets.
North America and pharma customers anchor 2025 demand
North America held the largest regional share in 2025 at 45%. Pharmaceutical and biopharmaceutical companies were also the largest end-user group at 45%. They use HPLC for drug development, purity assessment, release testing and stability monitoring.
Demand is also supported by impurity profiling, food analysis and environmental testing. Advances in UHPLC separation, automated method development and sensitive detection let laboratories handle complex samples and improve workflow efficiency.
HPLC/UHPLC systems and analytical HPLC lead segments
HPLC/UHPLC systems took the largest product share in 2025 at 45%. They form the core platform for pharmaceutical quality control, research, food safety and environmental testing. Columns ranked second at 25%.
By technology, analytical HPLC led with 68% in 2025. Its routine use in identifying and quantifying compounds, including drug impurity profiling, stability testing, food additive analysis and contaminant detection, keeps it ahead of preparative, semi-preparative and micro/nano HPLC.
Waters launches peptide and lipid columns for GLP-1 and LNP work
Growing analytical complexity in peptide therapeutics and other advanced drug modalities is raising demand for high-resolution separations, specialized columns and sensitive impurity detection. In June 2026, Waters introduced BioResolve Peptide and GTxResolve Lipid columns to resolve closely related impurities in GLP-1 peptides, insulin and lipid nanoparticles. In May 2026, Agilent announced a fluorescence detector.
Thermo Fisher, Waters and Agilent lead a competition built on software and consumables
Thermo Fisher Scientific, Waters Corporation and Agilent Technologies are the top three players. Thermo Fisher addresses pharmaceutical quality control, impurity analysis and automated method development through its Vanquish systems and Chromeleon software. Waters serves research and method development with its ACQUITY platforms, specialized columns and Empower software. Agilent supports clinical and diagnostic LC-MS workflows through its Infinity LC Clinical Edition offerings, alongside broader HPLC/UHPLC lines.
Competition centers on separation performance, detection sensitivity, workflow automation and software integration. Systems, pumps and detectors generate equipment revenue. Columns and consumables add repeat purchases through routine testing and replacement across the installed base. The report notes that these trends reflect changes in product demand, not a quantified shift in global revenue shares.
Leading players are pursuing mergers, collaborations, partnerships and acquisitions to expand technology portfolios, strengthen molecular diagnostics capabilities and broaden geographic presence.